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Traditional biomarkers in narcolepsy
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AbstrAct
This study was thought to characterized clinical and laboratory findings of a narcoleptic 
patients in an out patients unit at São Paulo, Brazil. Method: 28 patients underwent 
polysomnographic recordings (PSG) and Multiple Sleep Latency Test (MSLT) were analyzed 
according to standard criteria. The analysis of HLADQB1*0602 allele was performed by 
PCR. The Hypocretin-1 in cerebral spinal fluid (CSF) was measured using radioimmunoassay. 
Patients were divided in two groups according Hypocretin-1 level: Normal (N) - Hypocretin-1 
higher than 110pg/ml and Lower (L) Hypocretin-1 lower than 110 pg/ml. results: Only 4 
patients of the N group had cataplexy when compared with 14 members of the L group 
(p=0.0002). Discussion: This results were comparable with other authors, confirming the 
utility of using specific biomarkers (HLA-DQB1*0602 allele and Hypocretin-1 CSF level) in 
narcolepsy with cataplexy. However, the HLADQB1*0602 allele and Hypocretin-1 level are 
insufficient to diagnose of narcolepsy without cataplexy.
Key words: narcolepsy, cataplexy, cerebrospinal fluid, hypocretin-1, HLA-DQB1*0602, 
biomarkers.
biomarcadores tradicionias em narcolepsia: experiência de um centro de sono brasileiro
resuMo
Este estudo foi idealizado para avaliar as características clinicas e laboratoriais de uma 
população de narcolépticos atendidos num centro de referência na cidade de São Paulo 
(Brasil). Método: 28 pacientes realizaram polissonografia e teste de múltiplas latências do 
sono segundo critérios internacionais. O alelo HLADQB1*0602 foi identificado por PCR. 
A Hipocretina-1 no líquido cefalorradiano (LCR) foi mensurada por radioimunoensaio. Os 
pacientes foram divididos em 2 grupos conforme o nível de Hipocretina-1. Normal (N) - 
Hypocretin-1 >110pg/ml e baixa (B) - Hypocretina-1 <110pg/ml. resultados: Somente 4 
pacientes do grupo N tinham cataplexia quando comparados com 14 pacientes do grupo B 
(p=0,0002). Discussão: Estes resultados foram comparáveis com outros autores, confirmando 
a utilidade do uso de biomarcadores específicos (HLA-DQB1*0602 e nível da hipocretina-1 
no LCR) em narcolepsia com cataplexia. Porém, o alelo HLADQB1*0602 e a dosagem 
da Hipocretina-1 são insuficientes para o diagnóstico da narcolepsia sem cataplexia. 
Palavras-chave: narcolepsia, cataplexia, líquido cefalorraquidiano, HLA-DQB1*0602, 
biomarcadores.
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Narcolepsy is a sleep disorder char-
acterized by excessive sleepiness and in 
many patients associated to cataplexy 
and/or hypnagogic hallucinations, and/or 
sleep paralysis, and sleep fragmentation1. 
The International Classification of Sleep 
Disorders (ICSD-2) recognizes two main 
forms of narcolepsy: with and without cat-
aplexy2. Patients with narcolepsy with cat-
aplexy have excessive daytime sleepiness 
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and typical cataplexy is defined as short and sudden loss 
of muscle tone that occurs frequently after intense emo-
tions. Narcoleptic patients without cataplexy present ex-
cessive daytime sleepiness without cataplexy, and could 
present hypnagogic hallucinations, and/or sleep paral-
ysis. The electrophysiological diagnosis of narcolepsy is 
characterized by a latency of sleep lower than 8 minutes 
and two or more sleep onset REM periods (SOREMP) 
during Multiple Sleep Latency Test (MSLT). The HLA-
DQB1*0602 allele is prevalent in 95% of patients with cat-
aplexy, and has been highlighted in less than 50% of pa-
tients without cataplexy3. The Hypocretin-1 level in the 
cerebrospinal fluid (CSF) is lower than 110 pg/ml in al-
most all patients with typical cataplexy (narcolepsy/cata-
plexy syndrome)4,5. Only 5% of all patients with narcolep-
sy without cataplexy or atypical cataplexy would have this 
characteristic of CSF. Nowadays, the association among 
clinical presentation, electrophysiological features and the 
biological markers (HLA-DQB1*0602 allele and Hypocre-
tin-1) is the gold standard to diagnostic of narcolepsy2. 
Worldwide, there are a limited number of places with a 
large experience in working with narcoleptic patients. No 
study, as far as we know, has described complete presen-
tation of clinical and laboratory patients with narcolepsy, 
in a specific medical service in South America. The main 
objective of this study was to describe the relationship be-
tween clinical characteristics, polysomnography, MSLT, 
HLADQB1* 0602 allele prevalence, and CSF Hypocre-
tin-1 level in a group of outpatients with narcolepsy from 
the Sleep Institute, UNIFESP, São Paulo SP, Brazil.
METHOD
The study was approved by the Ethics and Research 
Committee of UNIFESP, code number 1802/07 and all 
Table 1. Clinical and laboratorial features of the patients with narcolepsy. 
Age 
(years) Sex
Hypocretin-1 
(pg/ml) HLA
Latency of 
MLST (min) SOREMP Cataplexy
Sleep 
paralysis
Hypnagogic 
Hallucinations
Sleep 
paralysis
33 M 0.0 P 0.1 4 yes no no no
38 M 0.0 P 0.2 4 yes no no no
44 M 0.0 P 2 4 yes yes yes yes
30 M 0.0 P 3 4 yes yes yes yes
27 M 0.0 P 3 4 yes yes yes yes
32 F 0.0 P 3 4 yes yes yes yes
34 F 0.0 P 2 5 yes yes yes yes
23 M 0.0 P 1 5 yes yes yes yes
66 F 0.0 P 4 4 yes yes yes yes
65 M 0.0 P 2 5 yes yes yes yes
32 F 0.0 P 2 5 yes yes yes yes
44 M 50.8 P 2 5 yes no no no
40 F 58.2 P 2 3 yes yes yes yes
33 M 93.2 P 1 4 yes yes yes yes
58 M 414.5 N 3 2 no yes yes yes
32 M 491.1 N 5 2 no no no no
27 F 529.2 N 3 5 no yes no yes
32 M 491.1 N 5 2 no no no no
37 M 135.4 P 3 5 yes yes yes yes
30 F 286.5 P 3 2 no yes yes yes
30 F 527.2 P 5 3 no yes yes yes
32 F 602.9 P 2 3 no no no no
43 F 504.1 P 2 2 yes yes yes yes
45 M 685.1 P 3 2 no no no no
28 M 530.3 P 2 3 yes yes no yes
42 F 546.8 P 4 2 no no no no
43 F 554.3 P 5 3 no yes no yes
28 M 669.0 P 1 5 yes yes yes yes
MLST: multiple sleep latency test; SOREMP: sleep onset REM periods.
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patients had signed the informed consent form. Twen-
ty-eight patients with narcolepsy willingly agreed to par-
ticipate in the study. The ICSD-2 was used to diagnose 
narcolepsy: all patients complained of excessive daytime 
sleepiness, scored higher than 10 on the Epworth Sleepi-
ness Scale, some of them experienced REM-related sleep 
events (sleep paralysis, hypnagogic hallucination and/or 
cataplexy) and highlighted a sleep latency of less than 8 
minutes plus 2 or more SOREMP during MSLT6,7. No 
other sleep diseases had been identified. Neurological ex-
amination was normal in all patients. All patients under-
went standard PSG recordings: with electroencephalo-
gram, eletro-oculogram, chin electromyogram, electro-
cardiogram, oral/nasal airflow and nasal/canula, chest/
abdominal respiratory effort, oxymetry, snoring, and tibi-
al electromyogram. Respiratory events were evaluated ac-
cording to the recommendations of the 1999 Task Force 
of the American Academy of Sleep Medicine. Arousals 
and periodic leg movements were analyzed according to 
ASDA (1992) and ASDA (1993) criteria, respectively8-11. 
The MSLT was analyzed according to standard criteria7. 
The presence of DQB1*0602 was determined by PCR us-
ing the following primers: DQBF (5’- CCCGCAGAG-
GATTTCGTGTT - 3’) and DQBR (5’- AACTCCGC-
CCGGGTCCC - 3’) (Bioneer, Inc., Daejeon, Korea)12. Af-
ter the lumbar puncture, 10 ml of CSF was kept frozen 
(–80ºC), until used for Hypocretin-1 determination by a 
radioimmunoassay kit (Phoenix Pharmaceuticals, St. Jo-
seph, MO, USA)13. Patients were divided in two groups 
according Hypocretin-1 level: Normal (N), Hypocretin-1 
higher than 110 pg/ml and Lower (L) Hypocretin-1 lower 
than 110 pg/ml. Statistical analysis was carried using the 
Chi-squared test for qualitative data like clinical and de-
mographic features, and the t test or Mann-Whitney were 
used for quantitative data like sleep features.
RESULTS
The two groups of 14 patients were compared for 
sex and age after CSF analysis (Table 1). Only 4 patients 
(28.5%) of N group had cataplexy when compared with 
14 (100%) of L group (p=0.0002). There were no differ-
ences between N and L groups when compared with hyp-
nogogic hallucinations, and sleep paralysis. Gelineau’s tet-
rad (sleepiness, cataplexy, hypnagogic hallucinations, and 
sleep paralysis) was more prevalence in L group (Table 2). 
Mean sleep latency was lower in L group (1.95±0.29 vs. 
3.23±0.3 minutes, p=0.008) and the SOREMP was high-
er in L group (4.28±0.16 vs. 2.92±0.33, p=0.01). HLA-
DQB1* 0602 allele was present in 14 patients (100%) of L 
group and in 10 patients (71%) of N group (p=0.20). Thir-
teen patients belonging to N group had Hypocretin-1 CSF 
level higher than 200 pg/ml and one patient had Hypo-
cretin-1 level between 110 to 200 pg/ml.
DISCUSSION
Fourteen of 18 (77%) patients with narcolepsy/cat-
aplexy syndrome have presented sleepiness character-
ized by the MLST, the prevalence of HLA-DQB1*0602 
allele increased, and the Hypocretin-1 CSF level scored 
below 110 pg/ml. Other narcoleptic features like hypna-
gogic hallucinations and sleep paralysis were no more fre-
quent in patients according Hypocretin-1 level. The prev-
alence of the HLA-DQB1*0602 allele was higher than ex-
pected in patients with Hypocretin-1 level above 110 pg/
ml when compared with other studies14,15. A possible ex-
planation about these results is the prompt acceptation to 
be part of the study by the more affected patients. How-
ever, the higher prevalence of cataplexy in our L group 
of patients is comparable with other authors13. Interest-
ingly, one patient with Hypocretin-1 level of 135.4 pg/ml 
and two patients with Hypocretin level above 200 pg/ml 
had narcolepsy/cataplexy syndrome with Gelineau’s tet-
rad. The cut-off value of Hypocretin-1 level for diagnosis 
in CSF patients has been discussed13. Other author has 
been described narcolepsy/cataplexy syndrome in patient 
with Hypocretin-1 between 110 and 200 pg/ml, for ex-
ample15. The differential diagnosis of some patients with 
sleepiness is a challenge, especially patients who have no 
narcolepsy/cataplexy syndrome and when they have other 
comorbidities14. Although the important and with high-
er sensibility and specificity for narcolepsy/cataplexy syn-
drome, our findings confirm that these biological mark-
ers are insufficient to help for the diagnosis of narcolep-
tic patients without cataplexy. 
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